Nykode Therapeutics ASA
OSE:NYKD
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.134
21.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NYKD stock under the Base Case scenario is 0.188 NOK. Compared to the current market price of 2.134 NOK, Nykode Therapeutics ASA is Overvalued by 91%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Nykode Therapeutics ASA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NYKD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Nykode Therapeutics ASA
Balance Sheet Decomposition
Nykode Therapeutics ASA
Current Assets | 140m |
Cash & Short-Term Investments | 136.5m |
Receivables | 3.5m |
Non-Current Assets | 39.9m |
PP&E | 9.3m |
Intangibles | 72k |
Other Non-Current Assets | 30.5m |
Current Liabilities | 15.1m |
Accounts Payable | 3.4m |
Other Current Liabilities | 11.7m |
Non-Current Liabilities | 12.7m |
Long-Term Debt | 3.4m |
Other Non-Current Liabilities | 9.3m |
Earnings Waterfall
Nykode Therapeutics ASA
Revenue
|
6.1m
USD
|
Operating Expenses
|
-65m
USD
|
Operating Income
|
-58.9m
USD
|
Other Expenses
|
20.9m
USD
|
Net Income
|
-37.9m
USD
|
Free Cash Flow Analysis
Nykode Therapeutics ASA
USD | |
Free Cash Flow | USD |
Nykode Therapeutics announced a significant strategic repositioning focusing their VB10.16 program on locally advanced cervical cancer and metastatic head and neck cancer. This decision, driven by feasibility and market potential, led to the discontinuation of the C-04 trial. Despite a net loss of $7.4 million in Q2, Nykode maintained a robust cash position of $136.5 million. They also highlighted promising data in their autoimmune platform and mRNA vaccine technologies, and reaffirmed commitments to their Genentech and Regeneron partnerships.
What is Earnings Call?
NYKD Profitability Score
Profitability Due Diligence
Nykode Therapeutics ASA's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Nykode Therapeutics ASA's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
NYKD Solvency Score
Solvency Due Diligence
Nykode Therapeutics ASA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Nykode Therapeutics ASA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NYKD Price Targets Summary
Nykode Therapeutics ASA
According to Wall Street analysts, the average 1-year price target for NYKD is 23.052 NOK with a low forecast of 10.1 NOK and a high forecast of 52.5 NOK.
Dividends
Current shareholder yield for NYKD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Contact
IPO
Employees
Officers
The intrinsic value of one NYKD stock under the Base Case scenario is 0.188 NOK.
Compared to the current market price of 2.134 NOK, Nykode Therapeutics ASA is Overvalued by 91%.